entertainment -WSS

entertainment

author：comprehensive 2025-09-28 01:36:32 - browse：55

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

hotspot

WSS

PBM executives asked to testify by House panel

Addiction doctors spar with methadone clinics over legislation

iTeos Therapeutics debuts first data on TIGIT

Class action alleges UnitedHealth concealed DOJ probe

Sepsis can kill a child within hours. Here's how hospitals are fighting back

iTeos Therapeutics debuts first data on TIGIT

leisure time

entertainment

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Report: NIH

Alkermes shareholders re

PBM executives asked to testify by House panel

ChatGPT in medicine: STAT answers readers' burning questions

Report: NIH

State Dept. review finds Biden bears some blame for Afghanistan failures

First Opinion Podcast: What happens when kids become caregivers?

How to save PrEP access — and even expand it

Novel spinal cord stimulator treats paralysis without surgery

focus

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

HHS's proposed rule does nothing to address the climate crisis

Average age of first period drops to 11.9 years, study shows

How a small hospital in rural Puerto Rico survived Hurricane Maria

iTeos Therapeutics debuts first data on TIGIT

Biohaven protein

explore

Wikipedia

hotspot

entertainment